AstraZeneca  announced the eight winners of the 2023 R&D Postdoctoral Challenge. and agreed to fund them to hold a postdoctoral position in one of the company's strategic research and development centers in Cambridge, England, Gaithersburg, USA, Boston, or Gothenburg, Sweden.

Postdoctoral programs in traditional industries generally provide predefined topics, while the R&D postdoctoral challenge is unique. AstraZeneca's unique program is now in its second year. It supports new scientists from all over the world to submit their own novel research proposals and gives them the opportunity to carry out these studies within the company. With the support of a skilled and multidisciplinary research team, the winners will carry out their own unique research projects and eventually accelerate the research and development of some of the most complex drugs for rare and chronic diseases in the world. By encouraging diversified thinking and global cooperation, AstraZeneca continues to break through the boundaries of science to provide life-changing drugs.

After standing out from nearly 100 applicants, eight finalists presented their research proposals at the AstraZeneca Discovery Center (DISC) in Cambridge, England. After listening to the statement, a jury composed of AstraZeneca and external life science leaders selected the winners based on scientific value and potential to have a real impact on patients.

Dr. Jenni Nordborg, Director of International Affairs of Lif, said: "Every finalist's speech on the stage and the novel methods displayed have deeply attracted me. But what inspires me more is their enthusiasm and passion for their key scientific fields, as well as their commitment to research that can help improve the return of patients.

Dr. Sharon Barr, executive vice president of biopharmaceutical research and development at AstraZeneca, said: "Scientific progress depends on whether we can cultivate a community that encourages the next generation of top scientists to put forward new ideas and ideas. We are pleased to welcome eight winners to AstraZeneca; this unique program demonstrates our commitment to supporting early talent and science-led innovation.

Dr. Seng Cheng, senior vice president of research and product development at Alexion, said: "The winners are willing to break the routine and pursue a project that completely changes the traditional postdoctoral program. They bring the passion and enthusiasm for innovation, as well as the collective ambition to accelerate drug discovery.

The winners will receive a postdoctoral research position fully funded by AstraZeneca. They can use the company's expertise, compounds, new tools and technologies, and guidance support to turn their innovative ideas into solutions for the benefit of patients worldwide.

As part of the AstraZeneca Early Talent Project, the R&D Postdoctoral Challenge is committed to supporting new scientists, providing them with opportunities for talent training and development, providing a diverse and inclusive working environment to support the vigorous development of scientific research.